
    
      De-identified banked genomic DNA samples derived from whole blood from subjects with
      suspected thrombophilia will be collected from one or more clinical sites. Three clinical
      laboratory sites will analyze the samples with the FII/FVL Test. Bi-directional DNA
      sequencing will be performed on all samples at an independent core reference laboratory.
    
  